
On November 24, Shenzhen Cell Valley was invited to attend the 2023 IVB Shenzhen Gene and Cell Therapy & Nucleic Acid Drug Summit, themed "Biotechnology Gives New Life," hosted by Shanghai Bomaishi Medical Services Co., Ltd., the Cell Medicine Branch of the China Food and Drug Corporation Quality and Safety Promotion Association, and the Vaccine and Biological Products Quality uation and Standards Professional Committee. The summit centered on revolutionary breakthroughs in innovative drugs such as gene and cell therapies, bringing together industry leaders, experts, and innovators to explore the potential of genetic medicine and give patients new opportunities for life.

Dr. Zhao Lijun, Head of R&D at our company, attended and delivered a keynote speech titled "Current Status and Prospects of Cell Therapy," providing an in-depth introduction to the development background, current status, and future trends of cell therapy, with a focus on the advantages of Shenzhen Cell Valley's core technology—industrial-grade retroviral vector technology (PackRV-SS). As an enterprise in the frontier innovative biotechnology field of cell and gene therapy, Shenzhen Cell Valley focuses on addressing bottlenecks in large-scale industrial production in the cell and gene therapy field. Through active participation in domestic and international exchange and cooperation, it has established strategic partnerships with leading domestic enterprises, medical institutions, research organizations, and universities, jointly advancing the R&D, clinical practice, and application of cell therapy drugs, supporting the translation of research achievements, and benefiting more patients.
Scan to follow our latest news Working hours: Monday to Friday, 9:00-18:00
Contact:Ms. Lai
Email:laijiaqi@rodael.com
Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)